» Articles » PMID: 20461753

Combined Classical Cytogenetics and Microarray-based Genomic Copy Number Analysis Reveal Frequent 3;5 Rearrangements in Clear Cell Renal Cell Carcinoma

Overview
Date 2010 May 13
PMID 20461753
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Karyotypic analysis and genomic copy number analysis with single nucleotide polymorphism (SNP)-based microarrays were compared with regard to the detection of recurrent genomic imbalances in 20 clear cell renal cell carcinomas (ccRCCs). Genomic imbalances were identified in 19 of 20 tumors by DNA copy number analysis and in 15 tumors by classical cytogenetics. A statistically significant correlation was observed between the number of genomic imbalances and tumor stage. The most common genomic imbalances were loss of 3p and gain of 5q. Other recurrent genomic imbalances seen in at least 15% of tumors included losses of 1p32.3-p33, 6q23.1-qter and 14q and gain of chromosome 7. The SNP-based arrays revealed losses of 3p in 16 of 20 tumors, with the highest frequency being at 3p21.31-p22.1 and 3p24.3-p25.3, the latter encompassing the VHL locus. One other tumor showed uniparental disomy of chromosome 3. Thus, altogether loss of 3p was identified in 17 of 20 (85%) cases. Fourteen tumors showed both overlapping losses of 3p and overlapping gains of 5q, and the karyotypic assessment performed in parallel revealed that these imbalances arose via unbalanced 3;5 translocations. Among the latter, there were common regions of loss at 3p21.3-pter and gain at 5q34-qter. These data suggest that DNA copy number analysis will supplant karyotypic analysis of tumor types such as ccRCC that are characterized by recurrent genomic imbalances, rather than balanced rearrangements. These findings also suggest that the 5q duplication/3p deficiency resulting from unbalanced 3;5 translocations conveys a proliferative advantage of particular importance in ccRCC tumorigenesis.

Citing Articles

Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma.

Correa A, Ruth K, Al-Saleem T, Pei J, Dulaimi E, Kister D Cancer Biol Ther. 2020; 21(5):424-431.

PMID: 32116106 PMC: 7515487. DOI: 10.1080/15384047.2020.1721251.


Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features.

Pei J, Al-Saleem T, Uzzo R, Dulaimi E, Testa J, Wei S Appl Immunohistochem Mol Morphol. 2020; 28(2):123-129.

PMID: 32044880 PMC: 8434675. DOI: 10.1097/PAI.0000000000000704.


The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Mehrazin R, Dulaimi E, Uzzo R, Devarjan K, Pei J, Smaldone M Ther Adv Urol. 2018; 10(1):3-10.

PMID: 29344091 PMC: 5761913. DOI: 10.1177/1756287217732660.


Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Mitsui Y, Shiina H, Kato T, Maekawa S, Hashimoto Y, Shiina M Mol Cancer Res. 2017; 15(7):884-895.

PMID: 28242813 PMC: 5890926. DOI: 10.1158/1541-7786.MCR-16-0444.


Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.

Ito T, Pei J, Dulaimi E, Menges C, Abbosh P, Smaldone M J Urol. 2015; 195(4 Pt 1):852-8.

PMID: 26602888 PMC: 4871784. DOI: 10.1016/j.juro.2015.10.180.


References
1.
Kardas I, Mrozek K, Babinska M, Krajka K, Hadaczek P, Lubinski J . Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep. 2005; 13(5):949-56. View

2.
Greshock J, Feng B, Nogueira C, Ivanova E, Perna I, Nathanson K . A comparison of DNA copy number profiling platforms. Cancer Res. 2007; 67(21):10173-80. DOI: 10.1158/0008-5472.CAN-07-2102. View

3.
Miura I, Siegfried J, Resau J, Keller S, Zhou J, Testa J . Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chromosomes Cancer. 1990; 2(4):328-38. DOI: 10.1002/gcc.2870020411. View

4.
Uzzo R, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg R . The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am. 2003; 30(3):423-36. DOI: 10.1016/s0094-0143(03)00021-1. View

5.
Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A . Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res. 2001; 61(21):7731-8. View